About Heikki Lanckriet, CEO – 00:18
About 4basebio UK Societas – 01:08
Admission to AIM – 04:15
Business focus – 04:47
Genomics assets – 06:16
Where are 4BB in terms of their development – 08:05
Market opportunity – 09:34
Non-viral delivery systems 10:12
Where is 4BB in the delivery of technology? – 11:59
Commercial summary – 12:39
4BB focus – summary – 13:46
Management & Capital Structure – 15:53
Financial expectations and near term objectives – 16:13
About 4basebio
4basebio UK Societas is a specialist life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for effective and safe delivery of these DNA based products to patients. Its main country of operation is the UK. The Company intends to become a market leader in the manufacture and supply of high purity, synthetic DNA for research, therapeutic and pharmacological use. The principal objective of 4bb is to validate and scale its DNA synthesis process with a view to manufacturing. Good Manufacturing Practice (“GMP”) grade DNA, suitable for use in gene therapies and DNA vaccines.
PIWORLD provides investors with the latest news and insight to listed companies and their management teams through either live or recorded results presentations, corporate overviews, management interviews and Capital Market Days. Together with interviews from leading fund managers, market specialists and esteemed private investors, we aim to keep the private investor community up to date and informed.
PIWORLD delivers high quality audio and video content to present anything from full-year and interim results to Capital Markets Days and corporate overviews. We bridge the gap between listed companies and the private investor community, who drive the share price and provide liquidity, providing a time and cost effective medium to reach this diverse and important audience.
